Abstract:Objective The aim of this study was to model the potential long-term disease progression and pharmacoeconomic value of sacubitril/valsartan for the treatment of essential hypertension from a Chinese healthcare system perspective. Methods A Markov cohort model with five health states was constructed to simulate the incidence of acute cardiovascular events and cost per quality-adjusted life-year (QALY) gained with sacubitril/valsartan compared with allisartan isoproxil and valsartan over a lifetime horizon with an annual cycle. Multivariable risk regression models derived from China-PAR data accompanied by hazard ratios were used to transform the dual mechanism of sacubitril/valsartan to lower blood pressure and left ventricular mass index into long-term fatal and non-fatal cardiovascular risks. Efficacy data were calculated using a network meta-analysis integrated by the results of clinical trials. Healthcare costs were determined from a real-world study and published literature, supplemented by expert opinion. Utilities were derived from literature. Both costs and health outcomes were discounted at 5.0% annually, and prices corresponded to 2021. Model validation, deterministic and probabilistic sensitivity analyses were conducted to test the robustness of results. Results For simulated patients with hypertension, sacubitril/valsartan reduced the rates of myocardial infarction by 6.67% and 6.39%, stroke by 9.38% and 8.98%, and heart failure hospitalization by 9.92% and 9.62% relative to allisartan isoproxil and valsartan, respectively. It was also associated with gains in life expectancy among hypertensive individuals of 0.362–0.382 years. Eventually, lifetime costs per patient were CN¥59,272 (US$9187) for sacubitril/valsartan, CN¥54,783 (US$8492) for allisartan isoproxil, and CN¥56,714 (US$8791) for valsartan; total QALYs were 11.38, 11.24, and 11.25, respectively. The incremental cost-effectiveness ratio was CN¥31,805/QALY (US$4930/QALY) compared with allisartan isoproxil, and CN¥19,247/QALY (US$2983/QALY) compared with valsartan, both of which are below the one time per-capita GDP of CN¥80,976/QALY (US$12,551/QALY) in China. Similar results were obtained in various extensive sensitivity analysis scenarios. Conclusions This was the first study to evaluate the cost effectiveness of sacubitril/valsartan in the treatment of hypertension. Sacubitril/valsartan compares favorably with allisartan isoproxil and valsartan in the Chinese setting, which is mainly due to its higher efficacy resulting in fewer cardiovascular events and ultimately less related mortality over time. The results could inform deliberations regarding reimbursement and access to this treatment in China and may provide reference for facilitating more reasonable and efficient allocation of limited resources in such low- and middle-income countries.

Comparative Effectiveness of Traditional Chinese Medicine vs. Losartan on Blood Pressure: Real-World Insights from RCT-Eligible Populations

A Practical Analysis Procedure on Generalizing Comparative Effectiveness in the Randomized Clinical Trial to the Real-world Trialeligible Population

Efficacy and safety of Songling Xuemaikang capsule for essential hypertension: A systematic review and meta-analysis of randomized controlled trials

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Traditional Chinese Patent Medicine for Primary Hypertension: A Bayesian Network Meta-Analysis

Efficacy and Safety of Valsartan/Amlodipine Single-Pill Combination in 11,422 Chinese Patients with Hypertension: an Observational Study

Effect on Blood Pressure Control of Switching from Valsartan Monotherapy to Losartan/hydrochlorothiazide in Asian Patients with Hypertension: Results of a Multicentre Open-Label Trial

Amlodipine/Valsartan 5/160 Mg Versus Valsartan 160 Mg In Chinese Hypertensives

China STudy of Valsartan/amlodipine Fixed-Dose Combination-Based Long-Term Blood Pressure Management in HypertenSive Patients: a One-Year Registry (china STATUS III)

A Comparison of Initial Treatment with Losartan/hctz Versus Losartan Monotherapy in Chinese Patients with Mild to Moderate Essential Hypertension.

[Network Meta-analysis of efficacy and safety of oral Chinese patent medicines combined with conventional western medicine in treatment of hypertension].

Chinese patent medicine combined with calcium channel blockers in the treatment of essential hypertension:a Bayes network meta-analysis and systematic review

Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

Efficacy and safety of single-pill amlodipine/losartan versus losartan in patients with inadequately controlled hypertension after losartan treatment: a multicenter, double-blind, randomized phase III clinical trial

Efficacy and Effectiveness of Valsartan/amlodipine and Valsartan/amlodipine/hydrochlorothiazide in Hypertension: Randomized Controlled Versus Observational Studies

Effects of traditional Chinese patent medicine on essential hypertension: a systematic review

Cost Effectiveness of the First‐in‐Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting

The comparative effects of oral Chinese patent medicines combined with western medicine in stable angina: A systematic review and network meta-analysis of 179 trials

Evaluation of blood pressure lowering effect by generic and brand-name antihypertensive drugs treatment: a multicenter prospective study in China

The effect of Chinese herbal medicine combined with western medicine on vascular endothelial function for patients with hypertension

Effects of Xuesaitong on the Pharmacokinetics of Losartan: an in Vivo UPLC-MS/MS Study